National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix J: Prospects for Immunizing Against Herpesvirus varicellae." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
313
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Appendix J
PROSPECTS FOR IMMUNIZING AGAINST HERPESVIRUS VARICELLAE

Disease Description

Varicella (chicken pox) is an acute communicable disease, primarily of childhood, caused by Herpesvirus varicellae (the varicella-zoster virus). The incubation period ranges from 10 to 21 days, with a median of 12 to 14 days. Susceptibility is universal, and because varicella is one of the most highly communicable infections known, the disease is almost universal as well. Diagnosis is relatively easy because of the characteristic vesicular rash. The principal route of spread appears to be by aerosolized small droplet rather than by direct contact with vesicular fluid or with the dried crusts of the skin lesions; paradoxically, virus is difficult to detect in oropharyngeal secretions, but is present in high titer in vesicular fluid from the lesions (Weller, 1982).

In normal children other than neonates, varicella is almost always a benign illness. Encephalitis occurs occasionally, but the most serious apparent complication is Reye’s syndrome. Although the nature of the relationship between varicella and Reye’s syndrome is uncertain, it is clear that varicella either plays a direct role in the pathogenesis of the syndrome or acts as a surrogate or marker for some concurrent condition that predisposes children to the disorder.

Adults are much more likely to experience significant morbidity or even mortality due to varicella. Varicella pneumonia, which may or may not be complicated by secondary bacterial pneumonia, is the principal complication in adults, although encephalitis also occurs.

Varicella-zoster virus shares with other members of the herpesvirus group the property of persistence or latency. In the case of varicella-zoster, the sensory ganglia have been suggested as the principal site of latency, but this has not been proved (Weller, 1982). Reactivation of the virus secondary to advancing age, stress, immunosuppression, and perhaps other factors, results in herpes zoster (shingles), a painful and prolonged eruption of typical herpetic lesions involving

The advice and assistance of S.Plotkin, S.Preblud, and T.Weller in the preparation of this appendix are gratefully acknowledged. The committee assumes full responsibility for any judgments or assumptions.

Page
313
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 313

OCR for page 314

OCR for page 315

OCR for page 316

OCR for page 317

OCR for page 318

OCR for page 319

OCR for page 320

OCR for page 321

OCR for page 322

OCR for page 323

OCR for page 331

OCR for page 332

OCR for page 333

OCR for page 334

OCR for page 335

OCR for page 336

OCR for page 337

OCR for page 338

OCR for page 339

OCR for page 340

OCR for page 341